First patient dosed in izokibep trial for patients with active AS

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS). 

“Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief Development Officer. “Working closely with our partner Affibody, the Inmagene team is excited to develop a potentially best-in-class treatment to improve the condition and quality of life of AS patients globally.” 

ASPIRE is a global Phase II, multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of izokibep for the treatment of patients with active ankylosing spondylitis (NCT04795141).  

Inmagene is responsible for all key development activities for the ASPIRE trial, including protocol design, study implementation and oversight. Inmagene has received IND approval/clearance in the US, Mainland China, South Korea, and Taiwan for the ASPIRE trial. 

“The ASPIRE study is an important trial to investigate the efficacy of izokibep for AS patients, leveraging the strong safety data from our prior studies”, commented Fredrik Frejd, CSO of Affibody. “We expect that both Affibody and Inmagene will be able to use the information from this study to advance the program in additional IL-17 driven indications.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free